ProBiotix Health launches CholBiomeBP for blood pressure support

September 10, 2020

ProBiotix Health, an OptiBiotix Health PLC subsidiary company, launched a tri-layer tablet, CholBiomeBP, that combines four science-backed ingredients to support hypertension and cardiovascular health.

ProBiotix Health, an OptiBiotix Health PLC subsidiary company based in the United Kingdom, launched a tri-layer tablet, CholBiomeBP, that combines four science-backed ingredients to support hypertension and cardiovascular health, including the company’s probiotic strain LPLDL, thiamine (vitamin B1), the amino acid L-arginine, and coenzyme Q10 (CoQ10). 

“We are thrilled to launch CholBiomeBP as part of the CholBiome brand portfolio,” said Mikkel Hvid-Hansen, commercial director at ProBiotix, in a press release. “CholBiomeBP is a natural food supplement that, by combining all four ingredients together in a unique way, helps to support normal cardiac function, as recognized by the European Food Safety Authority (EFSA).”

According to ProBiotix Health, in an independent, 12-week human study featuring 40 adults with high blood pressure, CholBiomeBP decreased diastolic blood pressure and reduced systolic blood pressure. In addition, the supplement also decreased low-density lipoprotein (LDL) cholesterol and total cholesterol. 

“We’re pleased to announce that CholBiomeBP will be joining the OptiBiotix Online store and will be complementing our growing science-backed cardiovascular health range,” said Steven Riley, director of marketing and consumer sales at OptiBiotix, in a press release. “The blood pressure reducing supplement is a key part of our commercial growth and is an exciting step forward to support consumers on their journey towards a healthier lifestyle.